Turn Therapeutics grants 80K stock options
Turn Therapeutics Inc. reported that officer Zuraiz Chaudhary received an award of 80,000 employee stock options on April 1, 2026.
Rhea-AI Filing Summary
Turn Therapeutics Inc. reported that officer Zuraiz Chaudhary received an award of 80,000 employee stock options on April 1, 2026. These options allow the purchase of common stock at an exercise price of $3.12 per share, with no cash paid at grant.
After this award, Chaudhary holds 80,000 stock options directly. The options vest over time: 25% vests on the first anniversary of the grant date and the remaining 75% vests ratably over the following 36 months, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. This is a compensation grant, not an open‑market share purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
1 txn
Insider
Chaudhary Zuraiz
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee stock option (right to buy) | 80,000 | $0.00 | $0.00 |
Holdings After Transaction:
Employee stock option (right to buy) — 80,000 contracts (Direct)
Footnotes (1)
- F1. The option will vest as follows: 25% will vest on the first anniversary of the grant date, with the remaining 75% vesting ratably over the following 36 months, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.
Key Figures
Option grant size: 80,000 options
Exercise price: $3.12 per share
Post-grant option holdings: 80,000 options
+2 more
5 metrics
Option grant size
80,000 options
Employee stock option award to officer on April 1, 2026
Exercise price
$3.12 per share
Exercise price of employee stock options
Post-grant option holdings
80,000 options
Total options held directly after the transaction
Initial vesting tranche
25% of options
Vests on first anniversary of grant date
Remaining vesting period
75% over 36 months
Ratable vesting after first anniversary, subject to employment
Key Terms
Employee stock option, 2025 Omnibus Incentive Plan, vesting, grant date
4 terms
Employee stock option financial
"Employee stock option (right to buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
2025 Omnibus Incentive Plan financial
"the Issuer's 2025 Omnibus Incentive Plan"
An omnibus incentive plan is a company-wide program that authorizes awards of pay tied to performance and retention—such as stock options, restricted shares, cash bonuses and other rewards—here labeled for the year it was adopted (2025). Investors care because it affects how much ownership can be issued, dilutes existing shareholders, and aligns executives’ and employees’ incentives with company goals, similar to giving team members a stake in the outcome.
vesting financial
"25% will vest on the first anniversary of the grant date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
grant date financial
"25% will vest on the first anniversary of the grant date"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Turn Therapeutics (TTRX) insider Zuraiz Chaudhary report on this Form 4?
The Form 4 reports that officer Zuraiz Chaudhary received an award of 80,000 employee stock options. These options relate to Turn Therapeutics common stock and are structured as compensation rather than an open-market share purchase or sale.
How many Turn Therapeutics (TTRX) stock options were granted and at what exercise price?
Chaudhary was granted 80,000 employee stock options linked to Turn Therapeutics common stock. Each option carries an exercise price of $3.12 per share, meaning that is the price required to buy a share when the options are exercised in the future.
What is the vesting schedule for Zuraiz Chaudhary’s Turn Therapeutics (TTRX) options?
The options vest over roughly four years. Twenty-five percent vests on the first anniversary of the grant date, and the remaining 75% vests ratably over the following 36 months, conditioned on continued employment and plan terms.
What is the Turn Therapeutics (TTRX) 2025 Omnibus Incentive Plan mentioned in the Form 4?
The 2025 Omnibus Incentive Plan is the company program under which Chaudhary’s 80,000 stock options were granted. Vesting and other terms of the option award are governed by this plan and the related option agreement.
How many Turn Therapeutics (TTRX) options does Zuraiz Chaudhary hold after this transaction?
Following the reported grant, Chaudhary holds 80,000 employee stock options directly. These options give him the right to buy an equal number of Turn Therapeutics common shares at the $3.12 exercise price as they vest.
AI-generated analysis. How Rhea-AI works. Not financial advice.
